UpdatesPress Release (Revised)
Anthem Biosciences reported a strong quarter, with Q4 revenue hitting a record ₹610.9 Cr (up 26% YoY). FY26 consolidated revenue reached ₹2,124.3 Cr, and PAT surged over 30% to ₹591.8 Cr.
Anthem Biosciences LimitedANTHEM · Filed with the exchange
Robust CRDMO growth and healthy cash position signal strong future prospects.
No comments yet. Be the first.